EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes

Abdelrahman Saqr iD, Mahmoud Al-Kofahi iD, Moataz Mohamed iD, Casey Dorr iD, Rory P Remmel iD, Guillaume Onyeaghala iD, William S Oetting iD, Weihua Guan iD, Roslyn B Mannon iD, Arthur J Matas iD, Ajay Israni iD, Pamala A Jacobson iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Abdelrahman Saqr und 11 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Drug Interactions, Tacrolimus, Genotype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug–drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid–tacrolimus DDI differs by CYP3A4/5 genotypes.

Methods

Kidney transplant recipients ( n = 2462) were classified by the number of loss of function alleles (LOF) ( CYP3A5*3 , *6 and *7 and CYP3A4*22 ) and steroid use at each tacrolimus trough in the first 6 months post‐transplant. A population pharmacokinetic analysis was performed by nonlinear mixed‐effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R.

Results

Steroids were associated with modestly higher (3%–11.8%) tacrolimus clearance. Patients with 0‐LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2‐LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1‐LOF and 3/4‐LOFs, respectively.

Conclusions

Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ADrug InteractionsTacrolimusGenotypeImmunosuppressive AgentsKidney TransplantationHumansMaleFemaleMiddle AgedAdultAllelesAgedModels, BiologicalSteroids

Stichwörter der Autor:innen

CYP3AShiny appinteractionkidney transplantationpharmacogenomicssteroidstacrolimus

Substanzen

Cytochrome P-450 CYP3ATacrolimusImmunosuppressive AgentsCYP3A5 protein, humanCYP3A4 protein, humanSteroids

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.
  • Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Abdelrahman Saqr, Mahmoud Al-Kofahi, Moataz Mohamed, Casey Dorr, Rory P Remmel, Guillaume Onyeaghala, William S Oetting, Weihua Guan, Roslyn B Mannon, Arthur J Matas, Ajay Israni, Pamala A Jacobson

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Saqr, A., Al-Kofahi, M., Mohamed, M., Dorr, C., Remmel, R. P., Onyeaghala, G., Oetting, W. S., Guan, W., Mannon, R. B., Matas, A. J., Israni, A., & Jacobson, P. A. (2024). Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16172

Vancouver

Saqr A, Al-Kofahi M, Mohamed M, Dorr C, Remmel RP, Onyeaghala G, et al. Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16172

BibTeX
@article{Saqr2024,
  author = {Saqr, Abdelrahman and Al-Kofahi, Mahmoud and Mohamed, Moataz and Dorr, Casey and Remmel, Rory P and Onyeaghala, Guillaume and Oetting, William S and Guan, Weihua and Mannon, Roslyn B and Matas, Arthur J and Israni, Ajay and Jacobson, Pamala A},
  title = {Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16172}
}
Kostenlos starten →